OHSU in the news

AbbVie's Upadacitinib (RINVOQ®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

AbbVie October 07, 2021
"Non-radiographic axial spondyloarthritis affects a younger adult patient population which can have a significant impact during prime years of those dealing with the disease," said Atul Deodhar, M.D., professor of medicine and medical director of the Rheumatology Clinics for the Division of Arthritis and Rheumatic Diseases at Oregon Health & Science University. "These data show that upadacitinib has the potential to improve non-radiographic axial spondyloarthritis symptoms and help patients take control of their disease."

Proposed residency fixes: Are they realistic or just wishful thinking?

Medscape October 07, 2021
While discussing the findings and recommendations in a report he helped compile as part of a Coalition for Physician Accountability committee, George Mejicano, M.D., says: “Are we really producing what the doctors of the country need? I would argue, no."

Oregon nurses union floats plan to reduce burnout

OPB's Think Out Loud October 07, 2021
An Oregon Nurses Association study found 86% of OHSU nurses are experiencing fatigue, burnout and moral distress, and 60% are considering leaving the profession.

Vaccine mandate latest hurdle in Oregon nursing shortage

The Associated Press October 07, 2021
A report on an Oregon Nurses Association press conference where they discuss their study, which found 86% of OHSU nurses are experiencing fatigue, burnout and moral distress, and 60% are considering leaving the profession.

Novel therapies shake up the spectrum of breast cancer treatment

OncLive October 06, 2021
In an interview with OncLive on the topic of HER2-positive breast cancer, OHSU's Zahi Mitri, M.D., says “Overall, it is a very exciting time with a lot of new drugs coming on board, a lot of which will improve outcomes for our patients without requiring more chemotherapy.”

FDA removes ‘unnecessary hurdle’ impeding use of ultrasound imaging agent

Radiology Business October 06, 2021
In an announcement about the FDA removing hypersensitivity to blood and blood products as a contraindication for prescribing GE Healthcare’s Optison ultrasound enhancing agent for heart imaging, Jonathan Lindner, M.D., says ultrasound enhancing agents can improve diagnostic accuracy and echocardiogram interpretation, and that removing this contraindication “removes unnecessary hurdles to employing this valuable asset in cardiovascular imaging.”
See more stories